GEAP201814459A - Medical treatments based on anamorelin - Google Patents

Medical treatments based on anamorelin

Info

Publication number
GEAP201814459A
GEAP201814459A GEAP201814459A GEAP2018014459A GEAP201814459A GE AP201814459 A GEAP201814459 A GE AP201814459A GE AP201814459 A GEAP201814459 A GE AP201814459A GE AP2018014459 A GEAP2018014459 A GE AP2018014459A GE AP201814459 A GEAP201814459 A GE AP201814459A
Authority
GE
Georgia
Prior art keywords
anamorelin
medical treatments
treatments based
medical
patient
Prior art date
Application number
GEAP201814459A
Other languages
English (en)
Inventor
Enrico Baroni
Ruben Giorgino
William Mann
John Friend
William Polvino
Suzan Allen
Ming Lu
Elizabeth Duus
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEAP201814459(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of GEAP201814459A publication Critical patent/GEAP201814459A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GEAP201814459A 2014-09-04 2015-08-28 Medical treatments based on anamorelin GEAP201814459A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04

Publications (1)

Publication Number Publication Date
GEAP201814459A true GEAP201814459A (en) 2018-09-10

Family

ID=55436476

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201814459A GEAP201814459A (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin
GEAP201514459A GEP20186939B (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201514459A GEP20186939B (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Country Status (44)

Country Link
US (5) US9675600B2 (Direct)
EP (2) EP3188599B1 (Direct)
JP (3) JP6356907B2 (Direct)
KR (3) KR102307275B1 (Direct)
CN (5) CN113577073A (Direct)
AP (1) AP2017009772A0 (Direct)
AR (1) AR103118A1 (Direct)
AU (1) AU2015312231B2 (Direct)
BR (1) BR112017003552A2 (Direct)
CA (1) CA2959158A1 (Direct)
CL (1) CL2017000494A1 (Direct)
CO (1) CO2017003263A2 (Direct)
CR (1) CR20170121A (Direct)
CY (1) CY1122746T1 (Direct)
DK (1) DK3188599T3 (Direct)
DO (1) DOP2017000055A (Direct)
EA (1) EA035578B1 (Direct)
EC (1) ECSP17019893A (Direct)
ES (1) ES2761777T3 (Direct)
GE (2) GEAP201814459A (Direct)
HR (1) HRP20192345T1 (Direct)
HU (1) HUE046894T2 (Direct)
IL (1) IL250692B (Direct)
JO (1) JO3541B1 (Direct)
LT (1) LT3188599T (Direct)
MA (1) MA40607B1 (Direct)
MD (1) MD4710C1 (Direct)
ME (1) ME03597B (Direct)
MX (1) MX361741B (Direct)
MY (1) MY187167A (Direct)
NI (1) NI201700024A (Direct)
PE (1) PE20171109A1 (Direct)
PH (1) PH12017500392B1 (Direct)
PL (1) PL3188599T3 (Direct)
PT (1) PT3188599T (Direct)
RS (1) RS59751B1 (Direct)
SG (1) SG11201701567UA (Direct)
SI (1) SI3188599T1 (Direct)
SV (1) SV2017005400A (Direct)
TN (1) TN2017000040A1 (Direct)
TW (1) TWI639429B (Direct)
UA (1) UA120765C2 (Direct)
UY (1) UY36286A (Direct)
WO (1) WO2016036598A1 (Direct)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
PL3188599T3 (pl) 2014-09-04 2020-06-01 Helsinn Healthcare Sa Zabiegi medyczne w oparciu o anamorelinę
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. MAINTENANCE DOSE ORAL PEANUT IMMUNOTHERAPY
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
CN114630655A (zh) 2019-08-30 2022-06-14 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
BR112022005457A2 (pt) 2019-10-24 2022-06-21 Toray Industries Agente terapêutico ou profilático para caquexia
WO2023042158A1 (en) * 2021-09-17 2023-03-23 Helsinn Healthcare Sa Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
EP1735055A1 (en) 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
CN103772483A (zh) 2004-06-29 2014-05-07 赫尔辛医疗股份公司 （3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
TW201400506A (zh) * 2012-05-25 2014-01-01 Raqualia Pharma Inc 用於治療胃酸缺乏症之生長激素釋放肽受體促效劑
PL3188599T3 (pl) 2014-09-04 2020-06-01 Helsinn Healthcare Sa Zabiegi medyczne w oparciu o anamorelinę

Also Published As

Publication number Publication date
AP2017009772A0 (en) 2017-02-28
PH12017500392A1 (en) 2017-07-17
HRP20192345T1 (hr) 2020-03-20
JP6923486B2 (ja) 2021-08-18
PL3188599T3 (pl) 2020-06-01
TW201613587A (en) 2016-04-16
ECSP17019893A (es) 2017-05-31
BR112017003552A2 (pt) 2017-12-05
US10278964B2 (en) 2019-05-07
SG11201701567UA (en) 2017-03-30
US20170296526A1 (en) 2017-10-19
LT3188599T (lt) 2019-12-10
KR20180085047A (ko) 2018-07-25
EP3590338A2 (en) 2020-01-08
HUE046894T2 (hu) 2020-04-28
US9675600B2 (en) 2017-06-13
IL250692B (en) 2019-05-30
CN113577074A (zh) 2021-11-02
ES2761777T3 (es) 2020-05-21
CN107375285A (zh) 2017-11-24
EP3590338A3 (en) 2020-03-18
KR102234319B1 (ko) 2021-04-01
SV2017005400A (es) 2017-04-20
CN109172575A (zh) 2019-01-11
MA40607B1 (fr) 2019-11-29
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
KR20210035923A (ko) 2021-04-01
US11723902B2 (en) 2023-08-15
MX2017002825A (es) 2017-09-28
PT3188599T (pt) 2020-01-15
US20190175574A1 (en) 2019-06-13
JP7044918B2 (ja) 2022-03-30
CO2017003263A2 (es) 2017-07-28
TWI639429B (zh) 2018-11-01
UA120765C2 (uk) 2020-02-10
SI3188599T1 (sl) 2020-02-28
EP3188599A1 (en) 2017-07-12
CN107205389A (zh) 2017-09-26
CN113577073A (zh) 2021-11-02
RS59751B1 (sr) 2020-02-28
KR102307275B1 (ko) 2021-09-30
JP2018154655A (ja) 2018-10-04
EP3188599A4 (en) 2017-10-11
KR20170047372A (ko) 2017-05-04
WO2016036598A1 (en) 2016-03-10
CA2959158A1 (en) 2016-03-10
NZ729673A (en) 2023-09-29
MD20170025A2 (ro) 2017-07-31
CL2017000494A1 (es) 2017-09-15
EP3188599B1 (en) 2019-10-02
DOP2017000055A (es) 2017-08-15
US20240024303A1 (en) 2024-01-25
PE20171109A1 (es) 2017-08-07
KR101881264B1 (ko) 2018-07-23
JP2021080281A (ja) 2021-05-27
AU2015312231B2 (en) 2017-10-19
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
PH12017500392B1 (en) 2018-08-31
US10894041B2 (en) 2021-01-19
JP2017526695A (ja) 2017-09-14
US20160067236A1 (en) 2016-03-10
MX361741B (es) 2018-12-14
IL250692A0 (en) 2017-04-30
US20210093627A1 (en) 2021-04-01
CR20170121A (es) 2017-07-17
MD4710B1 (ro) 2020-09-30
AR103118A1 (es) 2017-04-19
JO3541B1 (ar) 2020-07-05
CY1122746T1 (el) 2021-03-12
JP6356907B2 (ja) 2018-07-11
ME03597B (me) 2020-07-20
NI201700024A (es) 2017-07-18
TN2017000040A1 (en) 2018-07-04
UY36286A (es) 2016-02-29
MY187167A (en) 2021-09-07
MD4710C1 (ro) 2021-04-30
AU2015312231A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
GEP20186939B (en) Medical treatments based on anamorelin
EA201790737A1 (ru) Комбинированная терапия
IL249065A0 (en) Combination therapies for the treatment of cancer
PH12016501978B1 (en) Treatment of nafld and nash
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
PL3851537T3 (pl) Leczenie hiperbilirubinemii
MX387283B (es) Tratamiento del cancer con tg02.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MY190411A (en) Improved uricase sequences and methods of treatment
PH12019500725A1 (en) Methods of treating acute kidney injury
EP4483955A3 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
EP3185884A4 (en) Combination therapy for treatment of cancer
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
IL250662B (en) Tissue protection devices for the treatment of heart failure and other conditions
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
MX2017009281A (es) Antihistamina para usar en el tratamiento de cancer de seno.
IL258316A (en) A combination of trazodone and gabapentin for the treatment of pain
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
HK40009521A (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
PH12016502111A1 (en) Drug for treatment of tinnitus patients
UA97456U (en) METHOD FOR THE TREATMENT OF PATIENTS WITH CERVICAL CANCER of II-III stage
GB201501800D0 (en) Treatment of medical conditions
PT3546585T (pt) Ácidos nucleicos compreendendo um intrão modificado para utilização no tratamento de hiperbilirrubinemia